River City Laboratory, LLC

River City Laboratory, LLC was paid $239K by Medicaid between Apr 2021 and Nov 2022, across 19 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 67% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in Missouri

Rank by total paid#26 of 61

Median peer was paid$85K

This provider vs. median2.8×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2021	827	$19K
2022	9,966	$220K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	67%	3,154	1,213	$160K
87811	Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19)	12%	1,390	334	$30K
G2024	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]) from an individual in a snf or by a laboratory on behalf of a hha, any specimen source	12%	2,744	419	$29K
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	3.4%	2,257	713	$8K
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	1.9%	213	181	$5K
G2023	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	1.5%	279	251	$4K
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	1.2%	268	217	$3K
87502	Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets	<1%	61	43	$151.75
87634		<1%	59	41	$61.77
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	<1%	61	42	$59.70
87581		<1%	59	41	$30.88
87651	Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe	<1%	62	43	$30.88

7 more codes

87631		0%	27	$0.00
87641		0%	26	$0.00
87500		0%	25	$0.00
87498		0%	27	$0.00
87486		0%	27	$0.00
87640		0%	29	$0.00
87088		0%	25	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialTRAYLOR, ASHLEY (CFO)